Clinical Trials Logo

Clinical Trial Summary

This is a pilot feasibility study that investigates antifungal therapy with caspofungin in patients at high-risk for developing invasive candidiasis in a critical care setting.


Clinical Trial Description

Hypothesis: In high-risk non-neutropenic participants in the ICU, the proportion of participants discontinued from study therapy in order to be empirically treated with antifungal therapy for suspected candidiasis outside of the context of this protocol is less than 20% (i.e., the upper bound of the 95% confidence interval for the observed proportion is less than 20%). ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01045798
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Terminated
Phase Phase 2
Start date December 2010
Completion date April 2012

See also
  Status Clinical Trial Phase
Recruiting NCT05763251 - Comparison of Uncomplicated Candidemia Therapy Duration in Children N/A
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT02491151 - Variability of Fluconazole Concentration in Critically Ill Patients N/A
Completed NCT01716988 - Pharmacokinetics of Micafungin in Critically Ill Patients N/A
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00786903 - Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen? N/A
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Not yet recruiting NCT05707832 - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Phase 3
Recruiting NCT03538912 - Early Discontinuation of Empirical Antifungal Therapy and Biomarkers N/A
Completed NCT02801682 - NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Completed NCT02164890 - Pharmacokinetics of Micafungin in Patients of Intensive Care Units Phase 4
Completed NCT02841501 - Genetic Susceptibility Factors for Candidemia.
Completed NCT01047267 - Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU) N/A
Completed NCT00672841 - β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients N/A
Completed NCT02734862 - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Phase 2
Completed NCT01773876 - Empirical Antifungal Treatment in ICUS Phase 3
Completed NCT00689338 - Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Phase 3